Magle Competitors

Stocks . Sweden . 
Stock . Magle Chemoswed Holding
MAGLE Stock  SEK 11.10  0.20  1.83%   
Magle Chemoswed Holding competes with Mendus AB, Ascelia Pharma, Corline Biomedical, Elicera Therapeutics, and Intervacc; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Magle Chemoswed competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Magle Chemoswed to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Magle Chemoswed Correlation with its peers.

Magle Chemoswed vs IRLAB Therapeutics Correlation

Very poor diversification

The correlation between Magle Chemoswed Holding and IRLAB-A is 0.83 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Magle Chemoswed Holding and IRLAB-A in the same portfolio, assuming nothing else is changed.

Moving together with Magle Stock

  0.88VITR Vitrolife ABPairCorr

Moving against Magle Stock

  0.92VOLV-B AB VolvoPairCorr
  0.92VOLV-A AB VolvoPairCorr
  0.92DMYD-B Diamyd Medical ABPairCorr
  0.92MER Meren Energy Earnings Call This WeekPairCorr
  0.88INDU-A Industrivarden AB serPairCorr
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Magle Chemoswed's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
7.4911.1014.71
Details
Intrinsic
Valuation
LowRealHigh
7.2710.8814.49
Details

Magle Chemoswed Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Magle Chemoswed and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Magle and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Magle Chemoswed Holding does not affect the price movement of the other competitor.

High positive correlations

KDEV
+ 0.69
CLBIO
IRLAB-A
+ 0.68
CLBIO
IRLAB-A
+ 0.67
KDEV
BIOWKS
+ 0.64
XINT
XINT
+ 0.53
IMMU
IRLAB-A
+ 0.53
ELIC
  

High negative correlations

KDEV
- 0.47
XINT
BIOWKS
- 0.45
ELIC
IRLAB-A
- 0.4
BIOWKS
IRLAB-A
- 0.33
XINT
BIOWKS
- 0.31
KDEV
CLBIO
- 0.3
ACE

Risk-Adjusted Indicators

There is a big difference between Magle Stock performing well and Magle Chemoswed Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Magle Chemoswed's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
IMMU  2.87 (0.24) 0.00  0.71  0.00 
 0.00 
 6.32 
(6.02)
 21.62 
ACE  2.63  0.07  0.02  0.13  3.16 
(2.82)
 5.43 
(3.96)
 17.09 
CLBIO  1.78 (0.30) 0.00  0.64  0.00 
 0.00 
 4.07 
(3.61)
 13.41 
ELIC  2.59 (0.23) 0.00  1.18  0.00 
 0.00 
 5.36 
(4.29)
 27.92 
IVACC  2.44 (0.38) 0.00 (0.58) 0.00 
 0.00 
 4.44 
(4.35)
 22.88 
XINT  2.69  0.06  0.00 (3.25) 3.13 
(4.51)
 6.67 
(6.90)
 15.72 
MOB  1.82 (0.16) 0.00 (0.21) 0.00 
 0.00 
 3.54 
(4.00)
 9.16 
KDEV  4.76 (1.22) 0.00 (2.84) 0.00 
 0.00 
 11.54 
(13.16)
 47.86 
BIOWKS  3.15  0.23  0.04 (0.23) 3.50 
(3.55)
 7.92 
(5.00)
 16.66 
IRLAB-A  2.35 (0.35) 0.00  0.38  0.00 
 0.00 
 4.79 
(5.56)
 14.42 

Magle Chemoswed Competitive Analysis

The better you understand Magle Chemoswed competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Magle Chemoswed's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Magle Chemoswed's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MAGLE IMMU ACE CLBIO ELIC IVACC XINT MOB KDEV BIOWKS
 1.83 
 11.10 
Magle
 1.02 
 4.85 
Mendus
 4.59 
 3.12 
Ascelia
 5.86 
 15.25 
Corline
 1.76 
 4.47 
Elicera
 16.47 
 0.71 
Intervacc
 7.14 
 0.26 
Xintela
 0.33 
 9.12 
Moberg
 0.00 
 0.29 
Karolinska
 5.50 
 3.07 
Bio
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Relatively risky
Unstable
Not too volatile
Unstable
Abnormally volatile
Out of control
Not too volatile
Out of control
Very risky
Market Performance
(90 Days Performance)
Weakest
Weakest
Soft
Weakest
Weakest
Weakest
Weak
Mild
Weakest
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Small
High
High
High
High
Risky
Low
High
Average
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Current Ratio
1.94
14.67
23.69
3.99
N/A
12.16
6.13
10.66
0.24
9.14
Net Asset
237.18 M
720.98 M
333.49 M
101.66 M
54.74 M
329.39 M
24.74 M
450.89 M
1.11 B
120.86 M
Profit Margin
0.0637
N/A
N/A
0.0228
N/A
N/A
N/A
N/A
N/A
-1.31
EBITDA
18.14 M
(128.28 M)
(129.45 M)
(6.88 M)
(13.11 M)
(23.15 M)
(54.43 M)
6.46 M
177.79 M
(8.6 M)
Operating Margin
0.0727
-69.15
N/A
0.0228
-23.3
-4.77
N/A
-97.71
-14.44
-1.27
Current Valuation
342.6 M
607.17 M
359.6 M
178.43 M
42.8 M
1.26 B
122.93 M
82.88 M
247.24 M
635.01 M
Price To Book
2.01
1.13
2.34
2.2
2.21
5.02
11.52
0.42
0.37
8.03
Retained Earnings
N/A
(100 M)
N/A
N/A
N/A
N/A
N/A
(65 M)
(1.85 B)
N/A
Current Asset
N/A
45 M
N/A
N/A
N/A
N/A
N/A
410 M
259 M
N/A
Beta
0.66
1.04
0.89
0.8
N/A
1.07
1.45
0.8
0.4
0.99
Number Of Employees
69
31
21
10
1
13
16
7
7
36
Shares Outstanding
10.8 M
199.4 M
33.67 M
21.49 M
19.78 M
50.49 M
307.57 M
98.27 M
267.28 M
34.87 M
Cash Flow From Operations
26.04 M
(138.03 M)
(116.56 M)
(4.83 M)
(14.29 M)
(25.46 M)
(42.89 M)
(15.3 M)
16.7 M
(13.37 M)
Total Debt
25.94 M
N/A
553 K
N/A
N/A
222 K
N/A
16.25 M
N/A
N/A
Return On Equity
0.0607
-0.21
-0.54
0.0075
-0.39
-0.17
-4.69
-0.0325
-0.11
-0.66
Z Score
6.0
N/A
N/A
N/A
N/A
N/A
-6.6
9.6
-1.4
N/A
Return On Asset
0.0251
-0.11
-0.33
0.0044
-0.23
-0.0991
-1.14
-0.0249
-0.0168
-0.35
Book Value Per Share
13.71
2.81
5.19
4.38
1.86
5.41
-0.008
5.43
4.56
2.55
Current Liabilities
N/A
9 M
N/A
N/A
N/A
N/A
N/A
50 M
9 M
N/A
Total Asset
237.18 M
720.98 M
333.49 M
101.66 M
54.74 M
329.39 M
24.74 M
450.89 M
1.11 B
120.86 M
Debt To Equity
0.31
0.2
N/A
N/A
N/A
N/A
N/A
0.013
177.8
N/A
Target Price
N/A
6.75
65.0
29.0
N/A
95.0
N/A
8.0
4.5
27.0
Shares Owned By Institutions
N/A
11.78
31.16
14.21
N/A
32.27
N/A
3.39
5.97
5.59
Market Capitalization
272.16 M
427.98 M
483.48 M
203.87 M
78.53 M
1.02 B
143.79 M
272.28 M
510.26 M
718.4 M
Price To Earning
133.33
-4.53
N/A
-19.42
N/A
N/A
-4.4
4.77
7.42
N/A
Price To Sales
2.22
354.29
N/A
6.44
106.48
125.83
5115.13
1097.86
204.27
19.71
Net Income
4.19 M
(130.1 M)
(125.9 M)
(6.92 M)
(13.12 M)
(29.38 M)
(58.39 M)
7.49 M
170.82 M
(12.94 M)
Earnings Per Share
0.91
-0.63
-3.67
0.03
-0.86
-0.67
-0.73
-0.36
0.86
-0.41
Shares Owned By Insiders
78.6
57.54
22.73
54.88
62.87
14.49
58.76
18.07
37.17
54.85
Revenue
132.15 M
N/A
N/A
7.06 M
587
5.24 M
N/A
209.68 M
2.17 M
21.91 M
Working Capital
N/A
36 M
N/A
N/A
N/A
N/A
N/A
360 M
250 M
N/A
Cash And Equivalents
24.01 M
155.31 M
219.15 M
41.63 M
N/A
148.98 M
11.14 M
36.6 M
42.4 M
46.35 M
Cash Per Share
2.4
3.94
9.69
1.45
N/A
2.97
0.53
2.82
1.85
2.4
Gross Profit
110.83 M
6 K
N/A
9.1 M
587
6.25 M
2.08 M
207 K
2.17 M
53.01 M
Day Typical Price
10.97
4.88
3.17
15.08
4.41
0.72
0.26
9.21
0.29
3.07
Accumulation Distribution
9.41
712.04
48434.08
12761.0
0.0915
0.1
0.0385
2662.32
N/A
44982.82
Market Facilitation Index
0.0015
0.0
0.0
0.0
0.42
0.08
0.01
0.0
N/A
0.0
Daily Balance Of Power
0.5
(0.25)
(0.52)
(0.47)
(0.19)
(1.75)
(2.00)
(0.07)
0.0
0.3556
Period Momentum Indicator
0.2
(0.05)
(0.15)
(0.95)
(0.08)
(0.14)
(0.02)
(0.03)
N/A
0.16
Rate Of Daily Change
1.02
0.99
0.95
0.94
0.98
0.84
0.93
1.0
1.0
1.05
Day Median Price
10.9
4.9
3.2
15.0
4.38
0.73
0.26
9.26
0.29
3.08
Price Action Indicator
0.3
(0.07)
(0.15)
(0.22)
0.05
(0.09)
(0.01)
(0.16)
N/A
0.075
Coefficient Of Variation
(501.31)
(1,610)
3048.77
(861.48)
(1,861)
(1,156)
5475.32
(1,956)
(716.25)
1989.65
Mean Deviation
2.78
2.87
2.63
1.78
2.59
2.44
2.69
1.82
4.76
3.15
Jensen Alpha
(0.79)
(0.24)
0.0656
(0.30)
(0.23)
(0.38)
0.0582
(0.16)
(1.22)
0.2279
Total Risk Alpha
(0.96)
(0.46)
(0.08)
(0.47)
(0.46)
(0.57)
(0.14)
(0.26)
(1.66)
(0.03)
Sortino Ratio
N/A
N/A
0.0161
N/A
N/A
N/A
0.0029
N/A
N/A
0.0398
Downside Variance
N/A
N/A
11.47
N/A
N/A
N/A
24.69
N/A
N/A
14.08
Standard Deviation
3.75
3.9
3.28
2.69
4.2
3.99
3.69
2.38
8.54
4.03
Kurtosis
0.8915
1.39
0.6006
3.42
8.7
9.43
(0.28)
0.5124
11.81
0.02
Potential Upside
6.21
6.32
5.43
4.07
5.36
4.44
6.67
3.54
11.54
7.92
Treynor Ratio
(0.92)
0.7056
0.1311
0.6359
1.18
(0.58)
(3.25)
(0.21)
(2.84)
(0.23)
Maximum Drawdown
20.42
21.62
17.09
13.41
27.92
22.88
15.72
9.16
47.86
16.66
Variance
14.08
15.24
10.78
7.25
17.63
15.92
13.64
5.68
72.94
16.23
Market Risk Adjusted Performance
(0.91)
0.7156
0.1411
0.6459
1.19
(0.57)
(3.24)
(0.20)
(2.83)
(0.22)
Risk Adjusted Performance
(0.15)
(0.04)
0.0337
(0.09)
(0.03)
(0.06)
0.0224
(0.03)
(0.10)
0.048
Skewness
(0.17)
0.557
(0.16)
0.2648
2.15
0.2023
(0.14)
(0.30)
(0.94)
0.4037
Semi Deviation
N/A
N/A
3.16
N/A
N/A
N/A
3.13
N/A
N/A
3.5
Information Ratio
(0.21)
(0.08)
0.0167
(0.14)
(0.07)
(0.1)
0.0039
(0.07)
(0.15)
0.0371
Value At Risk
(8.22)
(6.02)
(3.96)
(3.61)
(4.29)
(4.35)
(6.90)
(4.00)
(13.16)
(5.00)
Expected Short fall
N/A
N/A
(2.82)
N/A
N/A
N/A
(4.51)
N/A
N/A
(3.55)
Downside Deviation
N/A
N/A
3.39
N/A
N/A
N/A
4.97
N/A
N/A
3.75
Semi Variance
N/A
N/A
9.97
N/A
N/A
N/A
9.81
N/A
N/A
12.22

Magle Chemoswed Competition Performance Charts

Five steps to successful analysis of Magle Chemoswed Competition

Magle Chemoswed's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Magle Chemoswed Holding in relation to its competition. Magle Chemoswed's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Magle Chemoswed in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Magle Chemoswed's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Magle Chemoswed Holding, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Magle Chemoswed position

In addition to having Magle Chemoswed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Oil And Gas Thematic Idea Now

Oil And Gas
Oil And Gas Theme
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Magle Stock Analysis

When running Magle Chemoswed's price analysis, check to measure Magle Chemoswed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Magle Chemoswed is operating at the current time. Most of Magle Chemoswed's value examination focuses on studying past and present price action to predict the probability of Magle Chemoswed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Magle Chemoswed's price. Additionally, you may evaluate how the addition of Magle Chemoswed to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY